Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Review uri icon

Overview

abstract

  • For patients with metastatic prostate cancer, bone is the primary site of tumor localization and the major cause of disease-related morbidity and mortality. Hormonal therapy and chemotherapy alone cannot eradicate disease harbored in bone. The delivery of radiotherapy to the reservoir of disease is an approach previously only achievable using bone-seeking radiopharmaceuticals. Now, however, with the identification of tumor-specific targets, antibodies are being used to deliver radiotherapy to these sites. In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development.

publication date

  • May 1, 2004

Research

keywords

  • Bone Neoplasms
  • Prostatic Neoplasms
  • Radioimmunotherapy

Identity

Scopus Document Identifier

  • 5444262113

Digital Object Identifier (DOI)

  • 10.1007/s11912-004-0053-y

PubMed ID

  • 15066234

Additional Document Info

volume

  • 6

issue

  • 3